Sector Alpha Week of 2026-09-11
Not SEBI Registered !! Not Investment advice !!
Sector Alpha — machine-written from the numbers · Data as of 2026-09-11

Heranba Industries Ltd

HERANBA
Pesticides/Agrochemicals

Heranba Industries Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.

The sharpest disagreement: the price moved −48.0% in a year while annual EPS moved −2,580.5% — the difference is re-rating, and re-rating has to be repaid with earnings.

The price is in a downtrend (49 weeks in) while the P/E sits at the 39th percentile of its own 2-year range. Underneath, the last four quarters read improving — profit +11.2% year on year, and 149% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.

Price
₹172
−48.0% 1Y
P/E
24.3×
39th pctile
of its own 2-year range
Revenue (Jun 26)
₹383 Cr
−15.3% YoY
Profit (Jun 26)
₹7.0 Cr
+11.2% YoY
Operating margin
12.8%
+5.9 pp YoY
ROCE
−2%
FY26
ROIC
−2.2%
vs WACC 12.0% → −14.2 pp
Cash conversion
149%
of profit, last 3 FY
Unverified figures: Some figures on this page come from a second financial-data feed that could not be cross-checked against the primary source — the two do not share enough overlapping reported history to compare. They are drawn, because they are the only evidence there is, and every section carrying one is marked unverified. PEG is the exception: the quarterly curve is not drawn at all. PEG asks what is being paid for growth — both sides of that division come from the source that could not be checked, so it is withheld instead of marked.
01 · Price story

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Heranba Industries Ltd trades at ₹172, in a downtrend and 49 weeks into that stage. That is −17.4% against its own 200-day average. It sits at 6% of a 52-week range of ₹165 to ₹283. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (16 weeks and counting).

Today the stock is in a downtrend — week 49 of stage 4, confirmed. At ₹172 it trades −17.4% versus its 200-day average and sits at 6% of its 52-week range (₹165–₹283).

Sep 26: ₹172 Weekly closing price (₹) with 50- and 200-day averages; shaded bands mark the price stage (grey base, green advance, amber top, red decline). 3-year window.
−17.4% versus the 200-day line, week 49 of stage 4
Price50-day avg200-day avg
S4S4S2S4S4₹559₹453₹347₹241₹136₹172₹208Sep 23Jun 24Apr 25Jan 26Sep 26
S4S4S2S4S4₹559₹453₹347₹241₹136₹172₹208Sep 23Apr 25Sep 26
Beating or trailing, week by week since 2021 Each cell is one week from 2021 to now (296 weeks): the stock's trailing 13-week return minus the NIFTY 500's, green ahead / red behind (±25% ramp). Grey cells are the 13-week warm-up or weeks where the NIFTY 500 reading is not held.
trailing 13-week return vs the NIFTY 500
Mar 21Sep 26

Against the market, two honest reads. Cumulative: over the last 5.5 years the stock moved −79% while the NIFTY 500 moved +80% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (16 weeks and counting; last ahead the week of 2026-06-12) — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

02 · Valuation

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Heranba Industries Ltd trades at 24.3× P/E, mid-range by its own standards (39th percentile). Its long-run median P/E is 27.4×, measured across 2.0 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 24.3× is mid-range by its own standards (39th percentile), against a long-run median of 27.4× measured over 2.0 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

P/E 24.3× vs a 27.4× long-run median P/E, weekly (left axis); earnings per share, trailing twelve months, weekly (right axis). 2.0-year window; loss-period spikes above 45× shown pinned at the top. The eps (ttm) bars are red where the reading is lower than the quarter before.
mid-range by its own standards (39th percentile)
P/EMedianEPS (TTM) (quarterly)
47.6×₹28.238.2×₹21.228.9×₹14.119.5×₹7.110.1×₹0.0×24.30×₹11Jun 23Nov 23May 24Nov 24May 25
47.6×₹28.238.2×₹21.228.9×₹14.119.5×₹7.110.1×₹0.0×24.30×₹11Jun 23May 24May 25
P/E
24.3×
39th percentile of 2y

🚨 Why the multiple sits where it does: over the past year annual EPS moved −2,580.5% against a −48.0% price move — the price outran earnings, pushing the multiple UP its own range.

Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.

A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.

03 · Stage: No read

Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Heranba Industries Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 8 quarters across 2 curves, on partial evidence.

Growth, year by year: revenue +13.1% in FY26, profit −4,000.0% Year-over-year growth per fiscal year, %: revenue (left axis); net profit and EPS (right axis — profit growth swings far wider). Zero line drawn. Turnaround-year spikes shown pinned (▲).
Revenue YoYProfit YoYEPS YoY
15%−48%9.4%−116%4.2%−183%−1.0%−251%−6.1%−319%%%13.1%−300%FY23FY24FY26
15%−48%9.4%−116%4.2%−183%−1.0%−251%−6.1%−319%%%13.1%−300%FY23FY24FY26
Three growth curves, twelve quarters Year-on-year growth of trailing-twelve-month revenue (left axis), profit and EPS (right axis — they swing far wider), % at each quarter-end. Base-effect spikes shown pinned (▲). A missing point means that reading is not held for the quarter.
the trajectory the stage is read from · revenue rolling over
RevenueProfitEPS
30%80%21%−22%13%−124%3.8%−226%−5.0%−328%%%−2.6%−300%−300%Sep 23Dec 24Jun 26
30%80%21%−22%13%−124%3.8%−226%−5.0%−328%%%−2.6%−300%−300%Sep 23Dec 24Jun 26
ROCE Annual readings — the quarterly balance-sheet pieces this curve needs are not held for this stock, so the returns read moves once a year and carries less weight in the call.
the return curve, annual readings
ROCE
7.7%5.1%2.5%−0.1%−2.7%%−2%FY24FY25FY26
7.7%5.1%2.5%−0.1%−2.7%%−2%FY24FY25FY26
Revenue growth
Falling
latest −2.6% · span −2.6% to +27.8%
ROCE
Falling
latest −2.0% · span −2.0%–7.0%

Why it matters: with too little history, an honest page says so instead of guessing a trajectory.

Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.

Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.

Compound annual growth rate (%) Compound annual growth rate over each window, %. Revenue, profit and EPS from fiscal-year figures; share price is the price CAGR over the same spans. A dash = that window is not held, or the base was a loss.
1yr3yr5yr10yr
Revenue+13.1%+6.5%
Share price−48.0%−23.3%−26.1%
Revenue YoY (Jun 26)
−15.3%
latest quarter vs a year ago
Profit YoY (Jun 26)
+11.2%
latest quarter vs a year ago
Revenue 10y
6.5%
long-run compound pace
04 · 4-Factor Sector Score

4-Factor Sector Score

28.0/100 — rank 23 of 24 in Pesticides/Agrochemicals · 77% evidence confidence

Heranba Industries Ltd scores 28.0 out of 100 against the 24 companies it is compared with in Pesticides/Agrochemicals, ranking 23. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 8.9 + 2.8 + 10 + 6.3 = 28. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

05 · Revenue

Revenue Revenue is the top line: everything the company billed its customers in the period.

Heranba Industries Ltd reported ₹383 Cr of revenue in the Jun 26 quarter, −15.3% year on year. Over 3 years it has compounded at 6.5% a year. The last full year, FY26, came in at ₹1,595 Cr. The last four reported quarters add to ₹1,526 Cr.

FY26 revenue came in at ₹1,595 Cr (+13.1% on the year), capping 3 years at 6.5% compound. The latest quarter (Jun 26) printed ₹383 Cr, −15.3% year on year.

FY26 revenue ₹1,595 Cr (+13.1% YoY) Revenue bars, ₹ Cr (left); YoY growth-% line (right). 4-year window. A bar is red when it is lower than the year before.
6.5% a year over 3 years
RevenueYoY growth
1.7k15%1.3k9.4%8614.2%431−1.0%0−6.1%₹ Cr%₹1,59513.1%FY23FY24FY26
1.7k15%1.3k9.4%8614.2%431−1.0%0−6.1%₹ Cr%₹1,59513.1%FY23FY24FY26
Jun 26: ₹383 Cr (−15.3% YoY) Quarterly revenue bars, ₹ Cr (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Revenue (quarterly)YoY growth
56358%42338%28219%141−1.0%0−21%₹ Cr%₹383−15.3%Sep 23Dec 24Jun 26
56358%42338%28219%141−1.0%0−21%₹ Cr%₹383−15.3%Sep 23Dec 24Jun 26

Pace check: the last four quarters averaged −3.1% growth against the decade's 6.5% — the current year is running slower than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew −2.6% over the last 4 quarters against +9.3%/yr over the last 8 — rolling over.

06 · Operating margin

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Heranba Industries Ltd's operating margin is 12.8% in the Jun 26 quarter, +5.9 percentage points against the same quarter a year ago. Across 4 fiscal years the operating margin has ranged 4.3% to 12.0%. The current quarter is running above every full year in that window.

The latest quarter's operating margin is 12.8%, +5.9 pp against the same quarter a year ago. Across 4 fiscal years the operating margin has ranged 4.3%–12.0%.

Why the margin moved: operating margin went +5.9 pp year on year while gross margin went +10.0 pp — the gain came mostly from the gross line: input costs and pricing.

FY26: 4.3% Operating margin by fiscal year, %, line (left); year-on-year change in the margin, in percentage points, line (right). 4-year window.
within a 4.3–12.0% band over 4 years
operating marginYoY change (pp)
13%1.6%10%−0.5%8.1%−2.5%5.9%−4.5%3.7%−6.6%%%4.3%−2.7%FY23FY24FY26
13%1.6%10%−0.5%8.1%−2.5%5.9%−4.5%3.7%−6.6%%%4.3%−2.7%FY23FY24FY26
Jun 26: 12.8% operating margin (+5.9 pp YoY) Quarterly operating margin, %, line (left); year-on-year change in the margin, in percentage points, line (right). Last 12 quarters. Operating profit as a share of revenue, per quarter.
Operating marginYoY change (pp)
15%17%9.2%10%3.2%3.0%−2.9%−4.0%−9.0%−11%%%12.8%5.9%Sep 23Dec 24Jun 26
15%17%9.2%10%3.2%3.0%−2.9%−4.0%−9.0%−11%%%12.8%5.9%Sep 23Dec 24Jun 26
07 · Net profit

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Heranba Industries Ltd earned ₹7.0 Cr of net profit in the Jun 26 quarter, +11.2% year on year. The full FY26 year was a loss of ₹78.0 Cr. That is 1.8% of the quarter's revenue. The same quarter a year earlier earned ₹6.3 Cr. 6 of the last 12 reported quarters were loss-making.

Jun 26 profit was ₹7.0 Cr, +11.2% year on year. On the full year, FY26 printed ₹−78.0 Cr (−4,000.0%).

FY26 profit ₹−78.0 Cr (−4,000.0% YoY) Net profit bars, ₹ Cr (left); YoY growth-% line (right). 4-year window. A bar is red when it is lower than the year before.
Net profitYoY growth
119247%66−893%13−2,034%−40−3,174%−93−4,315%₹ Cr%₹−78−4,000%FY23FY24FY26
119247%66−893%13−2,034%−40−3,174%−93−4,315%₹ Cr%₹−78−4,000%FY23FY24FY26
Jun 26: ₹7.0 Cr (+11.2% YoY) Quarterly net profit bars, ₹ Cr (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Net profit (quarterly)YoY growth
4557%18−5.1%−10−67%−38−129%−66−192%₹ Cr%₹711.2%Sep 23Dec 24Jun 26
4557%18−5.1%−10−67%−38−129%−66−192%₹ Cr%₹711.2%Sep 23Dec 24Jun 26
08 · Cash flow — the router

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 149% of Heranba Industries Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹−96.0 Cr of operating cash against ₹−78.0 Cr of profit. After ₹79.0 Cr of capital spending, ₹−175 Cr was left as free cash.

FY26: operating cash of ₹−96.0 Cr against reported profit of ₹−78.0 Cr, leaving free cash of ₹−175 Cr after ₹79.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 149% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

FY26: CFO ₹−96.0 Cr vs profit ₹−78.0 Cr Operating cash flow and net profit by fiscal year, ₹ Cr; the line is free cash flow (CFO minus capital spending). 4-year window, annual resolution.
149% of 3-year profit arrived as cash
Operating cashNet profitFree cash
13338−57−151−246₹ Cr₹−96₹−78₹−175FY23FY24FY26
13338−57−151−246₹ Cr₹−96₹−78₹−175FY23FY24FY26
FY26: CFO = 5,050% of profit (three-year rate 149%) Operating cash as a share of net profit, per fiscal year, % (line). Dashed line = 100% — every unit of profit arriving as cash; outlier years shown pinned.
Conversion100%
324%237%150%63%−24%%300%FY23FY24FY26
324%237%150%63%−24%%300%FY23FY24FY26

Why conversion sits at 149%: the cash cycle tightened 31 days between FY23 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.

Router verdict: the bigger cash user is investment — capital spending ran 3.4× depreciation over three years, so the next section's job is to check what that build-out is buying.

09 · Where the cash goes

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Heranba Industries Ltd's cash conversion cycle runs 123 days in FY26, down from 154 days in FY23. Capital spending ran ₹613 Cr over the last 3 years. At FY26 sales of ₹1,595 Cr each day of that cycle holds about ₹4.4 Cr, so roughly ₹537 Cr sits inside the business at any moment.

FY26: debtors at 135 days, inventory at 153 days — roughly 5.0 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 123 days, tighter than FY23's 154.

The full loop: cash goes out to suppliers and production on day 0; stock waits 153 days to sell; customers pay about 135 days after that; and suppliers themselves are paid at 166 days — netting out to the 123-day cycle.

In money terms: at FY26 sales of ₹1,595 Cr, each day of the cycle holds about ₹4.4 Cr — so the 123-day loop keeps roughly ₹537 Cr sitting inside the business at any moment.

FY26: a 123-day cash cycle Debtor days, inventory days, payable days and the cash conversion cycle by fiscal year. 4-year window.
−31 days vs FY23
Cash cycleInventory daysDebtor daysPayable days
19716513310169days123d153d135d166dFY23FY24FY26
19716513310169days123d153d135d166dFY23FY24FY26

On the investment side: capital spending of ₹613 Cr over the last 3 fiscal years against ₹181 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹21.0 Cr (FY26) — capacity paid for but not yet earning.

FY26: capex ₹79.0 Cr, work-in-progress ₹21.0 Cr Capital spending per fiscal year, ₹ Cr (bars); capital work-in-progress, ₹ Cr (line). Quarterly capital-spending history is not held for India — annual is the honest resolution.
a build-out
CapexWork-in-progress
353265177880₹ Cr₹79₹21FY24FY25FY26
353265177880₹ Cr₹79₹21FY24FY25FY26

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

10 · Return on capital

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified

Heranba Industries Ltd earns a ROCE of −2% in FY26. Return on invested capital clears the cost of that capital by −14.2 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is −4.9% net margin on 0.81× asset turns.

FY26 ROCE is −2%.

🚨 Why the return is what it is — the wiring (FY26): −4.9% net margin × 0.81× asset turns × 2.58× balance-sheet leverage ≈ −10.2% on equity. Margin does its share; leverage is a meaningful part of the equation.

The capstone test — ROIC − WACC: −2.2% − 12.0% = a −14.2 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.

FY26: ROCE −2% Return on capital employed by fiscal year, % (line); ROIC by fiscal year, % (line). 3-year window, dips included. Dashed line = the 12.0% cost of capital used on this page.
the full ladder
ROCEROIC (annual)WACC
13%9.0%4.8%0.7%−3.4%%−2%−2.3%FY24FY25FY26
13%9.0%4.8%0.7%−3.4%%−2%−2.3%FY24FY25FY26
Q4 FY26: ROCE −3.3% (TTM) vs WACC 12.0% Trailing-twelve-month ROCE and ROIC, per quarter, %; dashed line = the cost of capital. Last 12 quarters, put on a trailing-twelve-month basis and anchored to the annual figure.
ROCE (TTM)ROIC (TTM)WACC
13%8.8%4.3%0.0%−4.5%%−3.3%−1%Q1 FY24Q2 FY25Q4 FY26
13%8.8%4.3%0.0%−4.5%%−3.3%−1%Q1 FY24Q2 FY25Q4 FY26
11 · Debt

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified

Heranba Industries Ltd carries total debt of ₹576 Cr against shareholder equity of ₹770 Cr as of Mar 26, a debt-to-equity of 0.75. On the annual view that ratio went from 0.09 in FY22 to 0.75 in FY26. Read the returns elsewhere on this page with that leverage in mind.

Mar 26: total debt of ₹576 Cr against shareholder equity of ₹770 Cr — a debt-to-equity of 0.75. On the annual view, debt-to-equity went from 0.09 (FY22) to 0.75 (FY26). Read the returns on this page with that leverage in mind.

FY26: debt ₹576 Cr at 0.75× equity Total debt by fiscal year, ₹ Cr (bars); debt-to-equity, × (line). 5-year window.
Total debtDebt-to-equity
6220.8×4670.6×3110.4×1560.2×00.0×₹ Cr×₹5760.75×FY22FY24FY26
6220.8×4670.6×3110.4×1560.2×00.0×₹ Cr×₹5760.75×FY22FY24FY26
Mar 26: debt ₹576 Cr, debt-to-equity 0.75 Total debt per quarter, ₹ Cr (bars); debt-to-equity, × (line). Last 12 quarters. India reports the full balance sheet half-yearly, so the intervening quarter carries the prior reading forward.
Total debt (quarterly)Debt-to-equity
6220.8×4670.6×3110.4×1560.2×00.1×₹ Cr×₹5760.75×Jun 23Sep 24Mar 26
6220.8×4670.6×3110.4×1560.2×00.1×₹ Cr×₹5760.75×Jun 23Sep 24Mar 26
12 · Ownership

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

No holder of Heranba Industries Ltd moved a full percentage point over the last two years — the register is quiet. Promoters moved +0.0 points over the same window, to 75.0%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Domestic institutions: +0.3 points over 8 quarters to 0.3%; Promoters: +0.0 points over 8 quarters to 75.0%; Foreign institutions: +0.0 points over 8 quarters to 0.0%.

Fiscal-year ends: promoters +0.0 pts from Mar 24 to Mar 26 Shareholding at each fiscal-year end (March quarter), % of the company. 3 year-ends held.
PromotersForeign inst.Domestic inst.Public
81%59%37%16%−6.0%%75.0%0.1%0.3%24.7%Mar 24Mar 25Mar 26
81%59%37%16%−6.0%%75.0%0.1%0.3%24.7%Mar 24Mar 25Mar 26
A quiet register: no holder moved a full point in two years Shareholding by holder class, % of the company, quarterly, last 13 quarters.
PromotersForeign inst.Domestic inst.Public
81%59%37%16%−6.0%%75.0%0.0%0.3%24.8%Jun 23Dec 24Jun 26
81%59%37%16%−6.0%%75.0%0.0%0.3%24.8%Jun 23Dec 24Jun 26
13 · Safety line

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Heranba Industries Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

14 · Related companies · Pesticides/Agrochemicals
CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1Bayer CropScience LtdBAYERCROP 71.8/100Favorable setup94% evidence BASING 22.9/35 Revenue -2.8% · PAT 23.8% · OPM change 2 pp 100% evidence 21.2/25 ROCE 29.1% · OPM 20% 100% evidence 14.7/20 P/E 24.4× · PEG 1.28 100% evidence 13.0/20 RS sector 9.4% · RS bench -11% · 1Y -21.8%0 of 10 weeks ahead 70% evidence
Exact sum: 22.9 + 21.2 + 14.7 + 13 = 71.8 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.
2Titan Biotech Ltd524717 68.9/100Favorable setup82% evidence ASLEEP 29.1/35 Revenue 31.8% · PAT 38.7% · OPM change 2 pp 95% evidence 20.1/25 ROCE 22.8% · OPM 21% 76% evidence 5.7/20 P/E 53.3× · PEG — 50% evidence 14.0/20 RS sector 35.7% · RS bench 34.4% · 1Y 213.5%0 of 12 weeks ahead 100% evidence
Exact sum: 29.1 + 20.1 + 5.7 + 14 = 68.9 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.
3Sharda Cropchem LtdSHARDACROP 64.7/100Mixed-positive evidence100% evidence BASING 24.2/35 Revenue 18.5% · PAT 49% · OPM change -5 pp 100% evidence 19.6/25 ROCE 30.2% · OPM 17% 100% evidence 18.7/20 P/E 11× · PEG 0.26 100% evidence 2.2/20 RS sector -14.6% · RS bench -15.4% · 1Y -16.2%0 of 12 weeks ahead 100% evidence
Exact sum: 24.2 + 19.6 + 18.7 + 2.2 = 64.7 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -14.6% and the one-year return is -16.2%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
4Dharmaj Crop Guard LtdDHARMAJ 63.2/100Mixed-positive evidence74% evidence BASING 21.1/35 Revenue 8.5% · PAT 13.2% · OPM change 1 pp 95% evidence 15.9/25 ROCE 16.8% · OPM 15% 95% evidence 10.9/20 P/E 15.1× · PEG — 15% evidence 15.3/20 RS sector 5% · RS bench 4.5% · 1Y -27.7%0 of 10 weeks ahead 70% evidence
Exact sum: 21.1 + 15.9 + 10.9 + 15.3 = 63.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
5Punjab Chemicals & Crop Protection LtdPUNJABCHEM 60.5/100Mixed-positive evidence81% evidence BREAKING OUT 23.4/35 Revenue 8.2% · PAT 43.5% · OPM change 1 pp 95% evidence 17.9/25 ROCE 18.6% · OPM 12% 95% evidence 11.6/20 P/E 19.5× · PEG — 50% evidence 7.6/20 RS sector -6.2% · RS bench -5.8% · 1Y -4.2%5 of 10 weeks ahead 70% evidence
Exact sum: 23.4 + 17.9 + 11.6 + 7.6 = 60.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
6Advance Agrolife LtdADVANCE 56.9/100Mixed-positive evidence60% evidence BREAKING OUT 21.3/35 Revenue 48.4% · PAT 81.5% · OPM change 1 pp 95% evidence 14.8/25 ROCE 19.6% · OPM 11% 95% evidence 10.8/20 P/E 15.5× · PEG — 15% evidence 10.0/20 RS sector — · RS bench — · 1Y —8 of 10 weeks ahead 0% evidence
Exact sum: 21.3 + 14.8 + 10.8 + 10 = 56.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
7India Pesticides LtdIPL 52.9/100Mixed-positive evidence81% evidence BASING 20.1/35 Revenue 17% · PAT 10.1% · OPM change -2 pp 95% evidence 13.7/25 ROCE 16.6% · OPM 14% 95% evidence 14.1/20 P/E 14.3× · PEG — 50% evidence 5.0/20 RS sector -11.9% · RS bench -17.5% · 1Y -35.3%1 of 11 weeks ahead 70% evidence
Exact sum: 20.1 + 13.7 + 14.1 + 5 = 52.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
8Bhagiradha Chemicals & Industries LtdBHAGCHEM 51.9/100Mixed-positive evidence100% evidence ASLEEP 29.1/35 Revenue 33.7% · PAT 100% · OPM change 9 pp 100% evidence 7.0/25 ROCE 4.5% · OPM 16% 100% evidence 1.6/20 P/E 122× · PEG 8.06 100% evidence 14.2/20 RS sector 9.1% · RS bench 7.6% · 1Y -4.7%10 of 12 weeks ahead 100% evidence
Exact sum: 29.1 + 7 + 1.6 + 14.2 = 51.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
9Rallis India LtdRALLIS 50.9/100Mixed-positive evidence94% evidence BASING 20.4/35 Revenue 4.4% · PAT 24.4% · OPM change 2 pp 100% evidence 10.6/25 ROCE 14.1% · OPM 18% 100% evidence 11.5/20 P/E 17.2× · PEG 2.15 100% evidence 8.4/20 RS sector -1.8% · RS bench -19% · 1Y -43.5%0 of 10 weeks ahead 70% evidence
Exact sum: 20.4 + 10.6 + 11.5 + 8.4 = 50.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
10Astec Lifesciences LtdASTEC 50.9/100Mixed-positive evidence69% evidence BASING 23.9/35 Revenue 9.4% · PAT 47.7% · OPM change 11.2 pp 71% evidence 3.2/25 ROCE -5.4% · OPM -0.8% 95% evidence 10.0/20 P/E — · PEG — 0% evidence 13.8/20 RS sector 5.1% · RS bench 3.6% · 1Y -17.7%2 of 12 weeks ahead 100% evidence
Exact sum: 23.9 + 3.2 + 10 + 13.8 = 50.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
11Jubilant Ingrevia LtdJUBLINGREA 50.5/100Mixed-positive evidence93% evidence TURNING 19.0/35 Revenue 11% · PAT 11.2% · OPM change 1 pp 100% evidence 10.6/25 ROCE 11.4% · OPM 15% 100% evidence 6.1/20 P/E 33× · PEG 2.41 65% evidence 14.8/20 RS sector 0.7% · RS bench -0.6% · 1Y -8.3%5 of 12 weeks ahead 100% evidence
Exact sum: 19 + 10.6 + 6.1 + 14.8 = 50.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
12Sumitomo Chemical India LtdSUMICHEM 46.2/100Mixed-negative evidence94% evidence FADING 12.6/35 Revenue -3.6% · PAT 3.9% · OPM change 1 pp 100% evidence 19.0/25 ROCE 22.1% · OPM 22% 100% evidence 5.5/20 P/E 41.6× · PEG 4 100% evidence 9.1/20 RS sector -8.2% · RS bench 3.2% · 1Y -16.3%6 of 10 weeks ahead 70% evidence
Exact sum: 12.6 + 19 + 5.5 + 9.1 = 46.2 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
13NACL Industries LtdNACLIND 45.9/100Mixed-negative evidence100% evidence ASLEEP 29.1/35 Revenue 11.9% · PAT 100% · OPM change 3 pp 100% evidence 3.9/25 ROCE 8.1% · OPM 11% 100% evidence 3.7/20 P/E 142× · PEG 2.02 100% evidence 9.2/20 RS sector -4.3% · RS bench -5.8% · 1Y -35%7 of 12 weeks ahead 100% evidence
Exact sum: 29.1 + 3.9 + 3.7 + 9.2 = 45.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
14Meghmani Organics LtdMOL 45.8/100Mixed-negative evidence74% evidence BREAKING OUT 20.8/35 Revenue -7.8% · PAT 100% · OPM change 7 pp 95% evidence 7.8/25 ROCE 6.7% · OPM 18% 95% evidence 9.4/20 P/E 24.8× · PEG — 15% evidence 7.8/20 RS sector -33.7% · RS bench 7.6% · 1Y -22%7 of 10 weeks ahead 70% evidence
Exact sum: 20.8 + 7.8 + 9.4 + 7.8 = 45.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
15Excel Industries LtdEXCELINDUS 42.8/100Mixed-negative evidence74% evidence TURNING 12.4/35 Revenue 5.5% · PAT -20.4% · OPM change 0 pp 95% evidence 10.3/25 ROCE 6.2% · OPM 14% 95% evidence 10.4/20 P/E 17.3× · PEG — 15% evidence 9.7/20 RS sector -4.6% · RS bench 1.7% · 1Y -15.6%4 of 10 weeks ahead 70% evidence
Exact sum: 12.4 + 10.3 + 10.4 + 9.7 = 42.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
16UPL LtdUPL 42.2/100Mixed-negative evidence91% evidence BASING 17.1/35 Revenue 12.9% · PAT 98.4% · OPM change -2 pp 74% evidence 8.3/25 ROCE 10.1% · OPM 13% 100% evidence 12.2/20 P/E 24.5× · PEG 0.5 100% evidence 4.6/20 RS sector -11.6% · RS bench -12.5% · 1Y -16.8%0 of 12 weeks ahead 100% evidence
Exact sum: 17.1 + 8.3 + 12.2 + 4.6 = 42.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
17Bharat Rasayan LtdBHARATRAS 41.9/100Mixed-negative evidence87% evidence ASLEEP 10.8/35 Revenue -5.2% · PAT 3.6% · OPM change -3 pp 95% evidence 13.6/25 ROCE 16% · OPM 15% 95% evidence 14.4/20 P/E 13.2× · PEG — 50% evidence 3.1/20 RS sector -32.8% · RS bench -34% · 1Y -53.8%0 of 12 weeks ahead 100% evidence
Exact sum: 10.8 + 13.6 + 14.4 + 3.1 = 41.9 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
18Epigral LtdEPIGRAL 41.2/100Mixed-negative evidence94% evidence TURNING 7.5/35 Revenue 4.8% · PAT -37.4% · OPM change -2 pp 100% evidence 14.5/25 ROCE 15.5% · OPM 25% 100% evidence 14.4/20 P/E 18× · PEG 0.43 100% evidence 4.8/20 RS sector -32.9% · RS bench -6.6% · 1Y -35.9%1 of 10 weeks ahead 70% evidence
Exact sum: 7.5 + 14.5 + 14.4 + 4.8 = 41.2 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
19Dhanuka Agritech LtdDHANUKA 40.8/100Mixed-negative evidence100% evidence BASING 6.6/35 Revenue -5.6% · PAT -12.1% · OPM change -4 pp 100% evidence 16.2/25 ROCE 23.8% · OPM 12% 100% evidence 11.4/20 P/E 16.3× · PEG 1.72 100% evidence 6.6/20 RS sector -11% · RS bench -12.4% · 1Y -38.9%1 of 12 weeks ahead 100% evidence
Exact sum: 6.6 + 16.2 + 11.4 + 6.6 = 40.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
20Best Agrolife LtdBESTAGRO 40.0/100Mixed-negative evidence87% evidence TURNING 7.9/35 Revenue -24.1% · PAT -56.5% · OPM change 8 pp 95% evidence 9.1/25 ROCE 5.2% · OPM 20% 95% evidence 8.8/20 P/E 22.8× · PEG — 50% evidence 14.2/20 RS sector -0.4% · RS bench -1.8% · 1Y -27.2%5 of 12 weeks ahead 100% evidence
Exact sum: 7.9 + 9.1 + 8.8 + 14.2 = 40 · Decision use: Price leads the evidence: RS versus the benchmark is -1.8%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
21Insecticides India LtdINSECTICID 37.6/100Mixed-negative evidence87% evidence BASING 10.7/35 Revenue 1.3% · PAT -16.7% · OPM change -1 pp 95% evidence 10.8/25 ROCE 15.8% · OPM 11% 95% evidence 11.5/20 P/E 14.2× · PEG — 50% evidence 4.6/20 RS sector -6.7% · RS bench -8% · 1Y -23.4%1 of 12 weeks ahead 100% evidence
Exact sum: 10.7 + 10.8 + 11.5 + 4.6 = 37.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
22P I Industries LtdPIIND 35.3/100Mixed-negative evidence94% evidence BASING 4.7/35 Revenue -16.6% · PAT -27.8% · OPM change -5 pp 100% evidence 13.8/25 ROCE 15% · OPM 22% 100% evidence 9.5/20 P/E 31.7× · PEG 1.71 100% evidence 7.3/20 RS sector -3.4% · RS bench -25.1% · 1Y -38.3%0 of 10 weeks ahead 70% evidence
Exact sum: 4.7 + 13.8 + 9.5 + 7.3 = 35.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
23Heranba Industries Ltdthis pageHERANBA 28.0/100Adverse evidence77% evidence BASING 8.9/35 Revenue -2.6% · PAT -80% · OPM change 5.9 pp 95% evidence 2.8/25 ROCE -1.7% · OPM 12.8% 95% evidence 10.0/20 P/E — · PEG — 0% evidence 6.3/20 RS sector -19% · RS bench -20.3% · 1Y -48.7%0 of 12 weeks ahead 100% evidence
Exact sum: 8.9 + 2.8 + 10 + 6.3 = 28 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
24GSP Crop Science LtdGSPCROP 47.7/100Thin evidence · provisional38% evidence BREAKING OUT 14.2/35 Revenue — · PAT — · OPM change 0 pp 45% evidence 13.6/25 ROCE 18.9% · OPM 11% 76% evidence 9.9/20 P/E 21× · PEG — 15% evidence 10.0/20 RS sector — · RS bench — · 1Y —9 of 9 weeks ahead 0% evidence
Exact sum: 14.2 + 13.6 + 9.9 + 10 = 47.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

15 · Frequently asked questions

Frequently asked questions

What is Heranba Industries Ltd's share price today?

Heranba Industries Ltd trades at ₹172, −48.0% over the past year. The company is valued at ₹687 Cr. The stock sits at 6% of its 52-week range of ₹165–₹283, −17.4% versus its 200-day average. On the tape, the price is in a downtrend, 49 weeks in. — as of 11 September 2026.

What were Heranba Industries Ltd's latest quarterly results?

Heranba Industries Ltd reported revenue of ₹383 Cr and net profit of ₹7.0 Cr for the Jun 26 quarter. Revenue fell 15.3% and profit rose 11.2% year on year. Earnings per share were ₹1.78. The operating margin was 12.8%, 5.9 pp higher than a year earlier. — as of 11 September 2026.

What is Heranba Industries Ltd's revenue?

Heranba Industries Ltd reported revenue of ₹383 Cr in the Jun 26 quarter, −15.3% year on year. For the full FY26 fiscal year, revenue was ₹1,595 Cr (+13.1%). Over the last 3 years revenue compounded at 6.5% a year. — as of 11 September 2026.

What is Heranba Industries Ltd's profit?

Heranba Industries Ltd earned ₹7.0 Cr of net profit in the Jun 26 quarter, +11.2% year on year. Full-year FY26 profit was ₹−78.0 Cr. The operating margin ran 12.8% in the latest quarter. — as of 11 September 2026.

What is Heranba Industries Ltd's market cap?

Heranba Industries Ltd's market capitalisation is ₹687 Cr at a share price of ₹172. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.

What is Heranba Industries Ltd's P/E ratio?

Heranba Industries Ltd trades at a P/E of 24.3×, at the 39th percentile of its own 2-year range, against a long-run median of 27.4×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.

Does Heranba Industries Ltd pay a dividend?

Not in its latest year — Heranba Industries Ltd's dividend payout was 0% of profit in FY26. It did record a payout in 2 of its last 4 reported fiscal years, so there is a history but no current dividend. This page holds the payout ratio, not a per-share amount. — as of 11 September 2026.

Is Heranba Industries Ltd overvalued?

On its own history, Heranba Industries Ltd looks mid-range: its P/E of 24.3× sits at the 39th percentile of its 2-year range (long-run median 27.4×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 11 September 2026.

Is Heranba Industries Ltd growing?

Yes — Heranba Industries Ltd is growing: latest-quarter revenue −15.3% year on year, profit +11.2%, and the margin +5.9 pp at 12.8%. The earnings engine currently reads: improving — as of 11 September 2026.

How is Heranba Industries Ltd performing?

Heranba Industries Ltd is in a downtrend, 49 weeks in. Its latest quarter's revenue fell 15.3% and profit rose 11.2% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 16 weeks. This describes what the data did, not a rating. — as of 11 September 2026.

Is Heranba Industries Ltd in an uptrend?

No — the price is in a downtrend (week 49 of stage 4), trading −17.4% versus its 200-day average and at 6% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.

Is Heranba Industries Ltd beating the market?

Not lately — on a trailing-13-week view Heranba Industries Ltd is currently behind the NIFTY 500 (16 weeks and counting; last ahead the week of 2026-06-12), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 5.5 years the stock moved −79% against the NIFTY 500's +80% — behind the index over the full window. — as of 11 September 2026.

Will Heranba Industries Ltd's share price go up?

This page publishes no price forecast for Heranba Industries Ltd. What it measures instead: the share price is ₹172, the price is in a downtrend 49 weeks in. Its P/E of 24.3× sits at the 39th percentile of its own 2-year range. — as of 11 September 2026.

Who owns Heranba Industries Ltd?

Promoters hold 75.0% of Heranba Industries Ltd, foreign institutions 0.0%, domestic institutions 0.3% and the public 24.8% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 11 September 2026.

Does Heranba Industries Ltd have too much debt?

It is moderate — Heranba Industries Ltd's debt-to-equity is 0.76, and operating profit covers the interest bill 1×. FY26 borrowings were ₹576 Cr against equity of ₹762 Cr. Read the returns on this page with that leverage in mind — as of 11 September 2026.

What is Heranba Industries Ltd's capex?

Heranba Industries Ltd spent ₹613 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹79.0 Cr, with ₹21.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.

What is Heranba Industries Ltd's cash flow?

Heranba Industries Ltd consumed ₹96.0 Cr of operating cash in FY26 — cash flowed out rather than in (free cash flow: ₹−175 Cr). Reported profit that year was ₹−78.0 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 11 September 2026.

Is Heranba Industries Ltd's profit real cash?

Yes — over the last 3 fiscal years, 149% of Heranba Industries Ltd's reported profit arrived as operating cash. Though the latest year ran at 123% — the trend is the thing to watch. In FY26, operating cash was ₹−96.0 Cr against reported profit of ₹−78.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 11 September 2026.

Where is Heranba Industries Ltd in its business cycle?

Heranba Industries Ltd's FY26 operating margin was 4.3%, against a 4-year band of 4.3%–12.0%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 12.8%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.

What could break the Heranba Industries Ltd story?

The sharpest disagreement: the price moved −48.0% in a year while annual EPS moved −2,580.5% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.

Is Heranba Industries Ltd a stock worth studying right now?

This is not investment advice. The machine read: Heranba Industries Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.

Sector Alpha — machine-written from the numbers · Data as of 2026-09-11. Every chart on this page is drawn by deterministic code from the raw series — no forecasts, no price opinions, and nothing here is investment advice.

Not SEBI Registered !! Not Investment advice !!

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI